InDex's topical ulcerative colitis drug hits goal in phase 2b

A phase 2b trial of InDex Pharmaceuticals’ ulcerative colitis drug has met its primary endpoint. The trial linked use of the highest dose of the topical TLR9 agonist to a 15% improvement in the clinical remission rate over placebo.